Filtered By:
Specialty: Cardiology
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 1444 results found since Jan 2013.

Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.
In conclusion, some risk factors for CVD in hypertensive patients being treated with antihypertensive drugs with no history of CVD differed between CHD and stroke. These results suggest the importance of managing dyslipidemia with a statin for primary prevention of CHD, as well as the importance of hypertension therapy. PMID: 23865387 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Hypertension - July 18, 2013 Category: Cardiology Authors: Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Mori Y, Okuda Y, Hiramatsu K, the OMEGA Study Group Tags: Clin Exp Hypertens Source Type: research

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States Coronary Heart Disease
Conclusions In patients with prior MI or PAD who have not had a previous stroke or TIA, vorapaxar added to standard therapy is effective for long-term secondary prevention of thrombotic CV events, while increasing moderate or severe bleeding. Clinical Trial Registration URL: clinicaltrials.gov Unique Identifier: NCT00526474.
Source: JAHA:Journal of the American Heart Association - March 19, 2015 Category: Cardiology Authors: Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., Nicolau, J. C., Oude Ophuis, T., Scirica, B. M., Spinar, J., Theroux, P., Morrow, D. A. Tags: Coronary Heart Disease Source Type: research

Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials
Conclusion In CAD patients without HF, ACEi, but not ARBs decreases the risk of non-fatal MI, cardiovascular mortality and all-cause mortality, while both ACEi and ARBs decrease the risk of stroke.
Source: Cardiovascular Drugs and Therapy - February 9, 2016 Category: Cardiology Source Type: research

Carotid artery stenting outcomes in high-risk patients receiving best medical therapy: Results from a single high-volume interventional cardiology practice
Conclusions The study demonstrated acceptable clinical outcome results in patients with high medical comorbidities treated with CAS and intensive medical therapy. Adverse event rate in symptomatic patients did not exceed the guideline recommended range while in asymptomatic patients it was increased.
Source: Cor et Vasa - February 23, 2016 Category: Cardiology Source Type: research

Decline in Cardiovascular Mortality: Possible Causes and Implications.
Abstract If the control of infectious diseases was the public health success story of the first half of the 20th century, then the decline in mortality from coronary heart disease and stroke has been the success story of the century's past 4 decades. The early phase of this decline in coronary heart disease and stroke was unexpected and controversial when first reported in the mid-1970s, having followed 60 years of gradual increase as the US population aged. However, in 1978, the participants in a conference convened by the National Heart, Lung, and Blood Institute concluded that a significant recent downtick in c...
Source: Circulation Research - January 19, 2017 Category: Cardiology Authors: Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, Mussolino ME, Hsu LL, Addou E, Engelgau MM, Gordon D Tags: Circ Res Source Type: research

Secondary CV Prevention in South America in a Community Setting: The PURE Study
ConclusionsThere are large gaps in the use of proven medications for secondary prevention of cardiovascular disease in South America. Strategies to improve the sustained use of these medications will likely reduce cardiovascular disease burden substantially.
Source: Global Heart - July 5, 2018 Category: Cardiology Source Type: research

Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial
ConclusionsThe addition of multi-proteomic biomarkers to a clinical model in this population with diabetes and a recent MI allowed a better risk prediction and event reclassification, potentially helping for better risk assessment and targeted treatment decisions.Graphic abstractT2D type 2 diabetes,MI myocardial infarction,CV cardiovascular,HFH heart failure hospitalization,Δ delta,cNRI continuous net reclassification index,BNP brain natriuretic peptide,TRAILR2 trail receptor 2 (or death receptor 5),Gal-9 galectin-9,FGF23 fibroblast growth factor 23.
Source: Clinical Research in Cardiology - August 12, 2020 Category: Cardiology Source Type: research

Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease
Prog Cardiovasc Dis. 2022 May 19:S0033-0620(22)00046-9. doi: 10.1016/j.pcad.2022.05.003. Online ahead of print.ABSTRACTInternational guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with stati...
Source: Atherosclerosis - May 23, 2022 Category: Cardiology Authors: Kosmas I Paraskevas Peter Gloviczki Pier Luigi Antignani Anthony J Comerota Alan Dardik Alun H Davies Hans-Henning Eckstein Gianluca Faggioli Jose Fernandes E Fernandes Gustav Fraedrich George Geroulakos Jonathan Golledge Ajay Gupta Victor S Gurevich Arka Source Type: research

Statins Reduce Bleeding Risk in Patients Taking Oral Anticoagulants for Nonvalvular Atrial Fibrillation: A Retrospective Registry Study
ConclusionsStatins significantly reduced the risk of major bleeding, all-cause mortality, and ischemic events in patients with NVAF taking OACs. Their additive benefits should be considered in routine practice and thus be further researched.
Source: American Journal of Cardiovascular Drugs - November 16, 2022 Category: Cardiology Source Type: research

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
CONCLUSIONS: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).PMID:36876740 | DOI:10.1056/NEJMoa2215024
Source: Atherosclerosis - March 6, 2023 Category: Cardiology Authors: Steven E Nissen A Michael Lincoff Danielle Brennan Kausik K Ray Denise Mason John J P Kastelein Paul D Thompson Peter Libby Leslie Cho Jorge Plutzky Harold E Bays Patrick M Moriarty Venu Menon Diederick E Grobbee Michael J Louie Chien-Feng Chen Na Li LeAn Source Type: research

Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging With Cardiovascular Outcomes
CONCLUSIONS: Incidental CAC ≥100 was associated with an increased risk of all-cause death and adverse cardiovascular outcomes, beyond traditional risk factors. DL-CAC from routine non-ECG-gated CTs identifies patients at increased cardiovascular risk and holds promise as a tool for opportunistic screening to facilitate earlier intervention.PMID:37704309 | DOI:10.1016/j.jacc.2023.06.040
Source: Atherosclerosis - September 13, 2023 Category: Cardiology Authors: Allison W Peng Ramzi Dudum Sneha S Jain David J Maron Bhavik N Patel Nishith Khandwala David Eng Akshay S Chaudhari Alexander T Sandhu Fatima Rodriguez Source Type: research

Imaging the aortic arch to improve diagnostic and prognostic accuracy in transient ischemic attack patients
This study raises a final relevant question: since the prognosis of TIA patients worsens in proportion to the severity of AAA, what therapeutic options are available for these patients? The clinical guidelines recommend risk factor modification and therapy with statins (Class IIa, level of evidence C), an approach consistent with treatment of any patient affected by atherosclerosis. Treatment with coumadin or anti-platelet agents can be considered in patients with AAA >4 mm, i.e. severe AAA, but it remains very controversial because of a potential risk of thrombo-embolism (Class IIb, level of evidence C) . Finally, surgi...
Source: Atherosclerosis - November 25, 2013 Category: Cardiology Authors: Paolo Raggi Tags: Invited Commentaries Source Type: research

Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease A Meta-Analysis
ConclusionsIn elderly subjects at high CV risk without established CV disease, statins significantly reduce the incidence of MI and stroke, but do not significantly prolong survival in the short-term.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - November 25, 2013 Category: Cardiology Source Type: research